Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase RNA writing to reach previously undruggable diseases. The company is developing a first-of-its-kind RNA editing platform that can correct genetic mutations in a safe and reversible way.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/03/23 | $26,000,000 | Seed |
Andreessen Horowitz Eli Lilly and Company Hummingbird Ventures Pillar VC Playground Global Retinal Degeneration Fund | undisclosed |
